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SUMMARY  
Aim: Our objective was to investigate the effects and tolerability of ﬁxed-dose 
combination therapy on blood pressure and LDL in adults without elevated blood 
pressure or lipid levels. Methods: This was a double-blind randomised placebo-
controlled trial in residents of Kalaleh, Golestan, Iran. Following an 8-week 
placebo run-in period, 475 participants, aged 50 to 79 years, without cardiovascu­
lar disease, hypertension or hyperlipidaemia were randomised to ﬁxed-dose combi­
nation therapy with aspirin 81 mg, enalapril 2.5 mg, atorvastatin 20 mg and 
hydrochlorothiazide 12.5 mg (polypill) or placebo for a period of 12 months. The 
primary outcomes were changes in LDL-cholesterol, systolic and diastolic blood 
pressure and adverse reactions. Analysis was by intention-to-treat basis. Results: 
At baseline, there were differences in systolic blood pressure (6 mmHg). Taking 
account of baseline differences, at 12 months, polypill was associated with statisti­
cally signiﬁcant reductions in blood pressure (4.5 ⁄ 1.6 mmHg) and LDL-cholesterol 
(0.46 mmol ⁄ l). The study drug was well tolerated, but resulted in the modest 
reductions in blood pressure and lipid levels. Conclusion: The effects of the poly­
pill on blood pressure and lipid levels were less than anticipated, raising questions 
about the reliability of the reported compliance. There is a case for a fully powered 
trial of a polypill for the prevention of cardiovascular disease. 
evidence that aspirin is effective in primary preven-
Introduction 
tion of cardiovascular disease in individuals at high 
Cardiovascular disease (CVD) is the leading cause of risk (11). Incidence of cardiovascular disease 
death and disability worldwide and is presently lead- increases with age, therefore it has been argued 
ing cause of death and disability in low and middle- that ﬁxed-dose combination therapy (dubbed the 
income countries including Iran (1–3). Treatment of ‘polypill’) including antiplatelet agents, blood pres-
CVD is expensive, with more than 98% of health sure-lowering and lipid-lowering drugs could reduce 
care expenditure on CVD devoted to treatment incidence of cardiovascular disease in middle-aged 
rather than prevention, (1,3), and such costs are and older adults (12). The most novel aspect of this 
increasing as new therapies emerge (4). There is proposal has been to offer treatment to individuals 
therefore a need for coherent strategies for CVD whose risk factors are below usual treatment levels, 
prevention in low- and middle-income countries. but who are nevertheless at high risk of cardiovascu-
It has been established that there is a continuous lar disease because of their age and gender. There 
relationship between cardiovascular risk and both are a number of issues to consider in choosing the 
blood pressures and cholesterol levels (5–8). As low- exact formulation of a polypill, and a greater number 
ering elevated cholesterol or blood pressure reduces of active components promises greater effectiveness, 
cardiovascular risk, it is therefore plausible that low- but poses greater technical problems in develop­
ering these risk factors from average levels would ing the polypill (13). As a result of this, a number 
also reduce cardiovascular risk (9,10). There is of variations of the polypill are currently under 
What’s known? 
Drug treatments to lower lipid levels and drug 
treatments to lower blood pressure both reduce the 
incidence of cardiovascular disease. There is a good 
theoretical case for the use of ﬁxed-dose 
combination therapy (polypill) to reduce the 
incidence of cardiovascular disease in middle-aged 
and older adults. 
What’s new? 
In middle-aged and older adults in a developing 
country, ﬁxed-dose combination (polypill) therapy is 
well tolerated and compliance is satisfactory. Fixed-
dose combination (polypill) therapy results in the 
more modest reductions in lipid levels and blood 
pressure than anticipated. It is feasible to conduct 
a full-scale trial of prevention with ﬁxed-dose 
combination (polypill) therapy in a developing 
country. 
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development, including three, four or ﬁve active 
drugs (14–16). 
As the ﬁrst step in investigating the effectiveness 
of a polypill, it is necessary to establish whether 
combination therapy has the anticipated effects on 
blood pressure and cholesterol levels when taken by 
individuals with risk factors below usual treatment 
levels. It is also necessary to establish whether the 
medication is well tolerated and whether patients 
adhere to the medication. This kind of question is 
best addressed in a randomised controlled trial of 
relatively short duration. 
It has been argued that a prevention strategy based 
on a four drug polypill (two antihypertensive, aspirin 
and a statin) may be cost-effective, in low and 
middle-income countries (17–19). Iran is a middle-
income country where cardiovascular disease is a 
major cause of mortality (20). As part of a pro-
gramme to evaluate a polypill in Iran, we report on 
a double-blind randomised placebo-controlled trial 
investigating the effects of a four drug polypill in a 
middle-aged and older Iranian population. The trial 
was located in Golestan province (North-Eastern 
Iran), where cardiovascular disease accounts for 
47.5% of deaths in older adults and where obesity, 
hypertension and diabetes and metabolic syndrome 
are common (21–23). 
The aim of the study was to investigate the effects 
and tolerability of a polypill consisting of hydrochlo­
rothiazide 12.5 mg, aspirin 81 mg, enalapril 2.5 mg 
and atorvastatin 20 mg in middle-aged and elderly 
adults who conventionally deemed to be healthy with 
no cardiovascular risk factors except for the age > 50 
and would not currently be considered eligible for 
antihypertensive treatment. This was a four compo­
nent polypill, because it was judged that inclusion of 
a third antihypertensive drug or a higher dose of 
enalapril might result in hypotensive symptoms. 
Materials and methods 
This is a double-blind, placebo-controlled trial. All 
men aged 50 to 79 or women age 55 to 79, who were 
resident in Kalaleh, Golestan, North Iran, free from 
diagnosed cardiovascular disease at baseline and not 
already taking antihypertensive, statins or antiplatelet 
therapy were eligible for inclusion in the study. The 
study area is semi-rural with income levels around 
the national average and where the great majority of 
older persons are illiterate. 
Every household in the area was provided with 
information describing the study, it was publicised 
on local radio and television and individuals were 
invited to attend initial assessment if they met the 
inclusion criteria. At initial assessment, informed 
consent was obtained for collection of baseline data. 
Medical history was determined and a wide range of 
data was collected on lifestyle including diet, physical 
activity and smoking status. Two-seated blood pres­
sures, 1 min apart after 5 min rest, and standing 
blood pressure were estimated. Height and weight 
were measured and fasting blood samples were taken 
to assess complete blood count, CPK, ESR, CRP, 
lipid proﬁle, glucose, glycosylated haemoglobin, cre­
atinine and electrolytes, liver function tests and uric 
acid. 
All subjects were interviewed and educated about 
a healthy lifestyle and regular exercise by the enroll­
ing physician. They were given a well-designed picto­
rial pamphlet describing all aspects of a healthy 
lifestyle. Illiterate subjects were asked to have the 
pamphlet read to them by their children at home 
every week. Several programmes were arranged with 
the local Golestan television station to show and dis­
cuss healthy lifestyles. 
All family physicians, internists and cardiologists in 
the study region were invited to attend a lecture by 
the principle investigator (RM) about the polypill 
trial and the study goal, possible adverse effects of the 
polypill and their management. This lecture answered 
questions raised by local physicians, and secured pro­
fessional support for the study and collaboration with 
research team to reduce the burden of CVD. 
Individuals with contraindications to a component 
of the polypill were excluded. Contraindications to 
aspirin included hypersensitivity, previous bleeding 
peptic ulceration or recent peptic ulceration (within 
3 months). Contraindications to thiazide diuretics 
included gout or hyperuricaemia (> 8 lmol ⁄ l in men 
or > 6 lmol ⁄ l in women). Contraindications to sta­
tins included liver disease. Contraindications to fur­
ther blood pressure lowering included symptomatic 
postural hypotension or systolic blood pressure less 
than 90 mmHg at baseline. Individuals were excluded 
if they were unable to give full consent or to comply 
with the protocol because of mental or physical 
incapacity. Individuals with elevated total cholesterol 
levels or other laboratory abnormalities on initial 
assessment were initially reviewed and managed by 
the trial internist and subsequently referred to their 
family physician for further management. 
Following initial assessment, individuals who were 
eligible for inclusion and gave their informed consent 
were provided with 2 months supply of placebo tab­
lets for the run-in phase of the study. After the run-
in compliance was assessed by history and pill count, 
blood pressure and lipid levels were repeated. Partici­
pants who no longer met the inclusion criteria or 
whose compliance was poor (< 70% of pill intake) 
were excluded. Patients were provided with further 
ª 2010 Blackwell Publishing Ltd Int J Clin Pract, August 2010, 64, 9, 1220–1227 
1222 Pilot clinical trial of a polypill 
information on the study, and informed consent was 
obtained for randomisation. 
Participants were randomised by block randomisa­
tion through a computer-generated list of numbers. 
They were then allocated the correspondingly num­
bered blister packs containing either the ‘polypill’ as 
a single tablet or an identical placebo. Both polypill 
and placebo were manufactured by Alborz Darou 
pharmaceutical company. Participants and research­
ers were blind to the allocation. 
Participants were followed up at 1, 4, 8 and 
12 months. At follow-up visits, participants were 
asked about hospital admissions, cardiovascular 
events and possible adverse events. Researchers 
inquired about compliance and undertook pill 
counts, measured seated and standing blood pressure 
and took blood samples for laboratory tests. The 
study medication was dispensed, and patients were 
given a further follow-up appointment. 
Participants who reported possible adverse effects 
during follow up were assessed by the trial internist. 
If appropriate, the medication was temporarily with­
drawn to determine whether adverse effects were 
because of treatment. The internist restarted the 
study medication and if symptoms retuned after 
rechallenge, the study medication was discontinued. 
The primary outcomes were blood pressure and 
LDL-cholesterol. Secondary outcomes included total 
cholesterol, triglycerides, HDL-cholesterol and fasting 
glucose, major cardiovascular events and any adverse 
reactions to medication. Analysis was by intention-
to-treat basis. Mean systolic and diastolic blood pres­
sures, all lipid levels, triglyceride levels and fasting 
glucose levels were compared using analysis of 
covariance (ANCOVA) adjusting for baseline differ­
ences in the model. In addition to reported adverse 
effects, abnormal laboratory tests are reported as ele­
vations of CPK above 500 IU ⁄ l, elevations of AST 
above 50 IU ⁄ l or ALT above 40 IU ⁄ l and elevations 
of serum uric acid above 0.8 mmol ⁄ l. All analysis 
was carried out using SPSS version 14.0 (SPSS Inc., 
Chicago, IL, USA). 
Statistical analysis 
Assuming a pretreatment blood pressure of 
130 mmHg (standard deviation 20 mmHg), it was 
determined that a sample size of 504 was needed to 
have a power of 0.8 to detect a reduction in systolic 
blood pressure of 5 mmHg at a signiﬁcance level of 
0.05. 
The trial was registered with Controlled Clinical 
Trials (24). The IRB of the Digestive Disease 
Research Center of Shariati Hospital reviewed and 
approved the study protocol and the informed con­
sent forms. Ethical approval was obtained from the 
National Ethics Committee by the Deputy of 
Research at the Ministry of Health and Medical 
Education of the Islamic Republic of Iran. 
Results 
Between July 2006 and January 2007, 1733 people 
attended the assessment clinic. Of those assessed, 872 
were included in the run-in phase of the study: 50.5% 
of those assessed. The main reasons for exclusion 
were hypertension (434), diabetes mellitus (219), his­
tory of CVD (193), taking aspirin (148), hyperlipida­
emia (114), psychiatric illness (64), opium addiction 
(61) history of GI bleeding (40) and stroke (28). Sub­
jects could have more than one reason for exclusion. 
Most exclusions were because of subjects who were 
already on treatment or had indications for treatment 
and therefore could not be randomised to a placebo. 
During the run-in phase, 258 participants were 
excluded, following which a further 65 were excluded 
and 74 participants were not randomised. Reasons for 
exclusion are shown in Figure 1. The remaining 475 
participants were randomised (Figure 1). 
Baseline characteristics are shown in Table 1. At 
baseline, all characteristics of the two groups were sim­
ilar except that there were signiﬁcant differences in 
blood pressure between the intervention and control 
groups (5.5 mmHg systolic p = 0.001; 2.9 mmHg dia­
stolic p = 0.002), and more women were allocated to 
the intervention group (p = 0.041). Three hundred 
and forty-eight patients (348 ⁄ 475 = 73.3%) completed 
12 months of follow up. Follow up was more complete 
in the control group than the intervention group 
(78.2% vs. 68.5%; p = 0.016 by Chi squared test). Rea­
sons for losses to follow up are described in Figure 1. 
Mean systolic and diastolic blood pressures and 
mean lipid levels during follow up are shown in 
Table 2. With the last measure carried forward, by 
ANCOVA, adjusting for differences at baseline, sys­
tolic blood pressure was 4.5 mmHg (p < 0.001) and 
diastolic blood pressure 1.6 mmHg (p < 0.032) lower 
in the intervention than control group at the last 
follow-up visit. By the same method, LDL-cholesterol 
was 0.46 mmol ⁄ l (12.0%) lower (p < 0.001), and 
total cholesterol was 0.63 mmol ⁄ l (15.5%) lower 
(p < 0.001). Triglycerides were 0.16 mmol ⁄ l (11.3%) 
lower (p = 0.005), HDL-cholesterol was 0.01 mmol ⁄ l 
(0.9%) higher (p = 0.575) and fasting glucose was 
0.17 mmol ⁄ l (3.3%) lower (p = 0.008) in the inter­
vention than the control group. 
Pill counts suggested that compliance was reason­
able, with 89% of tablets taken in both intervention 
and control groups. One participant in the control 
group and none in the intervention group developed 
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Invited = 1986 
Control group  
Placebo 234 
Intervention group  
Polypill 241 
Randomised = 475 
Assessed for eligibility = 1733 
Did not consent = 4 
Did not meet eligibility criteria = 857 
Total excluded before run-in: 861 
Included in placebo run-in phase = 872 Did not consent = 7 
Did not meet eligibility criteria = 199 
(Lab) + 21 (loss to fu) 
Poor compliance / Adverse effects = 28 
Death = 3 
Total excluded during run-in: 258 
Discontinued medication: = 13 
Refused to come to KPC = 35 
Refused blood test = 4  
Hypertension = 7 
Cardiovascular disease = 6 
Total excluded at randomisation: 65 
Total not randomised: 74 
Followed up at 1 month = 212 lost to FU = 22 
Refused to come to KPC 13 
Refused blood sample  0 
Reluctant to take pill  9 
Loss to follow up  0 
Followed up at 1 month = 204 lost to FU = 37 
Refused to come to KPC 21 
Refused blood sample  3 
Reluctant to take pill  13 
Loss to follow up  0 
Followed up at 4 months = 187 lost to FU = 17 
Refused to come to KPC 11 
Refused blood sample  1 
Reluctant to take pill  4 
ADR: cough  1 
Loss to follow up  0 
Loss to follow up  0 
Loss to follow up  4 
Followed up at 8 months = 194 lost to FU = 6 
Refused to come to KPC 5 
Refused blood sample  0 
Reluctant to take pil  1 
Followed up at 12 months = 183 lost to FU = 9 
Refused to come to KPC 5 
Refused blood sample  1 
Reluctant to take pill  0 
ADR: cough  0 
Cardiovascular disease  1 
Followed up at 4 months = 200: lost to FU = 12 
Refused to come to KPC 7 
Refused blood sample  0 
Reluctant to take pill  5 
Loss to follow up  0 
Followed up at 8 months = 178 lost to FU = 9 
Refused to come to KPC 3 
Refused blood sample  1 
Reluctant to take pill  4 
ADR: cough  1 
Loss to follow up  0 
Followed up at 12 months = 165 lost to FU = 13 
Refused to come to KPC 4 
Refused blood sample  0 
Reluctant to take pill  1 
ADR: cough  0 
Loss to follow up  8 
1 Recruitment and follow up Figure 
1223 Pilot clinical trial of a polypill 
a non-fatal coronary attack. Two participants 700 IU ⁄ l were reported, and no participants reported 
assigned to the intervention and none assigned to clinical symptoms of myopathy. Abnormal liver func­
the control group discontinued the study medication tion tests (elevations of AST above 50 IU ⁄ l or ALT 
because of cough (Fisher’s exact test two sided above 40 IU ⁄ l) were observed in 43 intervention and 
p = 0.50). Six participants assigned to the control 38 control participants (Fishers exact p = 0.714). No 
and none assigned to the intervention were started participants were found to have evidence of liver dis­
on additional drugs for hypertension (Fisher’s exact ease. Elevations of serum uric acid above 0.8 mmol ⁄ l 
test two sided p = 0.03). These subjects had average were seen in 35 intervention and 31 control partici­
blood pressures of 150.2 ⁄ 89.2 mmHg at baseline. pants (Fishers exact p = 0.693). 
Other side effects were minor and did not result in 
the discontinuation of treatment. 
Discussion 
Elevations of CPK above 500 IU ⁄ l were observed in 
nine intervention and two control participants (Fish­ Our study is the ﬁrst test of the effectiveness of a 
ers exact p = 0.063). No elevations higher than polypill in individuals without previous risk factors. 
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Table 1 Baseline characteristics of intervention and control groups 
Parameters Polypill Placebo p values 
Number (total = 475) (n = 241) (n = 234) 
Age (years) ± SD 59.0 ± 6.5 59.1 ± 7.3 0.856 
Gender (% female) 37.8 28.6 0.041 
Systolic blood pressure (mmHg) ± SD 124.8 ± 17.3 130.3 ± 17.4 0.001 
Diastolic blood pressure (mmHg) ± SD 78.4 ± 10.4 81.2 ± 9.7 0.002 
Weight (kg) ± SD 68.7 ± 11.8 69.1 ± 12.1 0.729 
Body mass index (kg ⁄ m 2) ± SD 26.4 ± 4.3 26.0 ± 4.2 0.316 
Waist circumference (cm) ± SD 92.7 ± 12.0 91.6 ± 11.4 0.307 
Total cholesterol (mmol ⁄ l) ± SD 5.26 ± 1.01 5.26 ± 1.00 0.987 
LDL-cholesterol (mmol ⁄ l) ± SD 2.97 ± 0.68 3.02 ± 0.67 0.410 
HDL-cholesterol (mmol ⁄ l) ± SD 1.14 ± 0.27 1.10 ± 0.25 0.063 
Triglyceride (mmol ⁄ l) ± SD 1.42 (1.33–1.51) 1.48 (1.39–1.56) 0.382 
Fasting glucose (mmol ⁄ l) ± SD 5.16 ± 0.73 5.16 ± 0.87 0.971 
AST (IU ⁄ l) 95% CI 27.6 (24.6–31.0) 28.3 (25.1–31.8) 0.771 
ALT (IU ⁄ l) 95% CI 18.4 (16.1–20.9) 19.3 (16.8–22.1) 0.610 
CPK (95% CI) 92.3 (85.1–100.0) 95.9 (88.9–103.3) 0.491 
Na+ (mmol ⁄ l) 95% CI 144 (143.4–144.5) 143.8 (142.4–145.2) 0.825 
K+ (mmol ⁄ l) 95% CI 4.47 (4.43–4.52) 4.48 (4.44–4.52) 0.881 
Creatinine (mg ⁄ dl) 95% CI 0.96 (0.95–0.98) 0.98 (0.96–1) 0.301 
Smoking status (current, %) 19.1 23.5 0.263 
*Values for categorical variables are proportions. 
Table 2 Changes in primary and secondary outcomes adjusted for baseline differences 
Intervention Control GLM mean 
Measurement Visit (mean) N (mean) N difference p value 
Systolic BP Baseline 124.8 241 130.3 234 )4.5 < 0.001 
Final visit 121.1 241 129.0 234 
Diastolic BP* Baseline 78.4 240 81.2 234 )1.6 0.032 
Final visit 77.6 240 81.2 234 
Total Cholesterol Baseline 5.26 241 5.26 234 )0.63 < 0.001 
Final visit 4.37 241 4.99 234 
LDL-cholesterol Baseline 2.97 241 3.02 234 )0.46 < 0.001 
Final visit 2.37 241 2.87 234 
HDL-cholesterol* Baseline 1.14 240 1.10 234 0.01 0.575 
Final visit 1.24 240 1.21 234 
Triglycerides* Baseline 1.42 240 1.48 234 )0.16 0.005 
Final visit 1.42 240 1.60 234 
Fasting glucose* Baseline 5.16 240 5.16 234 )0.17 0.008 
Final visit 5.15 240 5.31 234 
*For each of these variables, one data item was missing from the database. 
We found that ﬁxed-dose combination treatment 
with aspirin 81 mg, hydrochlorothiazide 12.5 mg, 
atorvastatin 20 mg and enalapril 2.5 mg resulted in 
statistically signiﬁcant, but unexpectedly the modest 
reductions in LDL-cholesterol and systolic blood 
pressure. A half standard dose of thiazide and quar­
ter standard dose of ACE inhibitor would be 
expected to lower blood pressure by 12.0 ⁄ 6.0 mmHg 
in patients with a mean blood pressure of 
154 ⁄ 97 mmHg and by 6.5 ⁄ 2.0 mmHg reduction in 
this population with a mean blood pressure of 
125 ⁄ 78 mmHg (25). The observed effect was three 
quarters of this: 4.5 ⁄ 1.6 mmHg. Atorvastatin 20 mg 
would be expected to reduce LDL-cholesterol by 
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43% (9). The observed effect was a 15.5% reduction 
in LDL-cholesterol, about one-third of that pre­
dicted. The lower than expected effects on blood 
pressure and LDL-cholesterol are consistent with 
either poor compliance or with lack of drug efﬁcacy. 
Our reductions in blood pressure and LDL are 
slightly smaller than those reported in a recently 
published study of a ﬁve component polypill in 
India: 7.6 ⁄ 5.6 mmHg for blood pressure and 
0.70 mmol ⁄ l for LDL-cholesterol (26). However, the 
Indian study included three antihypertensive drugs 
and reported ﬁndings after 12 weeks of follow up, 
whereas we used two antihypertensive drugs and 
reported ﬁndings after 52 weeks. 
Further detailed investigation of compliance with 
the study medication was conducted by interviewing 
20 participants after the study had been completed. 
Participants indicated that they were happy to take 
the study medication daily despite realising that it 
may be an inactive placebo. Most participants admit­
ted to occasionally forgetting to take tablets, some­
times failing to take medications with them when 
travelling and during harvesting time being unable to 
attend the study centre before their supply of tablets 
had been completed. Some of the subjects were not 
at home when we called them to give the reminder 
(15%). Overall, compliance was estimated to be 
about 65–70%. This level of compliance suggests that 
the drug may have been less efﬁcacious than pre­
dicted. Further bioequivalence studies are planned to 
investigate this possibility. Furthermore, as we have 
longer follow up than the Indian trial (26), our esti­
mated compliance may be closer to the true situation 
when the medication is offered to the general popu­
lation in the long term. 
Our study has some weaknesses. We observed dif­
ferences in blood pressure and gender at baseline. 
This implies that there may have been deﬁciencies in 
the randomisation process which we have been 
unable to clarify. However, the analysis has 
attempted to deal with this by adjusting for differ­
ences at baseline. We also observed that although 
few adverse effects were reported, more patients dis­
continued the polypill than the placebo, particularly 
during the ﬁrst month of follow up. 
How effective is a polypill likely to be? Since the 
start of this study, there have been two further clini­
cal trials on the effects of aspirin in primary preven­
tion of CVD. We conducted a meta-analysis of the 
effects of aspirin in primary prevention, including 
the studies included in a previous meta-analysis and 
three subsequent clinical trials (11,27–34). Using a 
random effects model, relative risk of coronary heart 
disease (CHD) with aspirin is 0.82 (95% conﬁdence 
interval 0.69 to 0.98), and relative risk of stroke 
(CVA) is 0.93 (95% conﬁdence interval 0.84 to 
1.04). With 35% efﬁcacy (consistent with our ﬁnd­
ings of the effects of atorvastatin), we would expect a 
relative risks of 0.93 (0.820.35) for CHD and 0.97 
(0.930.35) for CVA. A 12 mmHg reduction in systolic 
blood pressure is predicted to be associated with rel­
ative risks of 0.75 and 0.65 for CHD and CVA 
respectively (6,35). With a 4.5 mmHg reduction in 
systolic blood pressure, we would expect relative risks 
of 0.90 (0.75(4.5�12)) for CHD and 0.85 (0.65(4.5�12)) 
for CVA. A 1.81 mmol ⁄ l reduction in LDL-choles­
terol would be associated with relative risks of 0.39 
and 0.83 on CHD and CVA respectively (9,11,12,25). 
With a 0.46 mmol ⁄ l reduction in LDL-cholesterol, 
we would expect relative risks of 0.79 (0.39(0.46�1.81)) 
(0.85(0.46�1.81)for CHD and 0.93 ) for CVA. The 
combined therapy therefore has a RR of 0.66 for 
CHD and 0.79 for CVA (9,11,25); (Table 3). Given 
that CHD accounts for about four-ﬁfths of CVD 
events, this equates to a relative risk of CVD of 0.69 
(3). Our ﬁndings are consistent with the more mod­
est reduction in CVD risk than that proposed by the 
authors of the recent Indian study (26). Indications 
from this pilot study are therefore that a four com­
ponent polypill has the potential to reduce the inci­
dence of CVD by about one-third. This effect size 
may be sufﬁcient to be cost-effective (17). However, 
larger effects have been observed with high-intensity 
statin treatment alone (36). Estimated effectiveness 
Table 3 Predicted effects of a polypill on coronary heart disease (CHD) and CVA 
Typical effect of treatment Effects of treatment with observed efﬁcacy 
Relative risk Relative risk 
Intervention Effect on risk factor CHD CVA Effect on risk factor CHD CVA 
Aspirin Typical compliance 0.82 0.93 35% efﬁcacy 0.93 0.97 
LDL-cholesterol 1.81 mmol ⁄ l 0.39 0.83 0.46 mmol ⁄ l 0.79 0.95 
SBP 12 mmHg 0.75 0.65 4.5 mmHg 0.90 0.85 
Total 0.25 0.52 0.66 0.79 
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depends on assumptions about the likely effects of 
LDL lowering. Using the more modest effect sizes 
derived from another meta-analysis gives an overall 
relative risk of CVD of 0.79 (37). Recent meta-analy­
sis has suggested that the risks and beneﬁts of aspirin 
are ﬁnely balanced: exclusion of aspirin, as suggested, 
would give an overall relative risk of 0.83 (38). To 
ensure that all subjects might beneﬁt from participa­
tion in this pilot study, the research ethics committee 
required that all study participants were offered 
advice on lifestyle modiﬁcation. We therefore made 
considerable efforts to educate the study population 
about the importance of lifestyle modiﬁcation in pre­
vention of CVD and provided all participants with 
an illustrated pamphlet, conducted several radio and 
television programmes to emphasise healthy life style. 
We also used the network of community women vol­
unteers to promote a healthy lifestyle in the Kalaleh 
district. This demonstrates that pharmacological pre­
vention need not preclude lifestyle changes. 
This pilot study illustrates the problems faced 
when trying to undertake primary prevention of 
CVD in a developing country such as Iran with high 
risk of CVD. These include obtaining informed 
consent in a population with low levels of literacy, 
ensuring compliance and maintaining adequate 
follow up. Overall, the clinical trial was conducted 
successfully. The polypill appears to have been well 
tolerated, compliance was reasonable and few signiﬁ­
cant adverse effects were reported. There remain, 
however, considerable challenges. Our ﬁndings raise 
questions about the bioequivalence of the polypill 
used in this trial, and further studies are needed to 
elucidate this. Increasing the dose of enalapril to 
5 mg or 10 mg would help increase the effect on 
blood pressure, as higher doses of ACE inhibitors are 
not associated with higher incidence of adverse drug 
reactions (25). Compliance may also be improved. 
Healthy people may be reluctant to take a regular 
medication and we suggest that a future large scale 
trial may therefore include people with CVD risk 
factors detected during the prerandomisation clinical 
or laboratory evaluation, as these have a greater 
capacity to beneﬁt from treatment and may be more 
likely to comply with treatment. A fully powered trial 
investigating the impact of the polypill on cardiovas­
cular events and all cause mortality is needed. Our 
ﬁndings conﬁrm the feasibility of such a trial. 
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